SummaryPopulations of the White-rumped Vulture Gyps bengalensis, Indian Vulture G. indicus and Slender-billed Vulture G. tenuirostris declined rapidly during the mid-1990s all over their ranges in the Indian subcontinent because of poisoning due to veterinary use of the non-steroidal anti-inflammatory drug diclofenac. This paper reports results from the latest in a series of road transect surveys conducted across northern, central, western and north-eastern India since the early 1990s. Results from the seven comparable surveys now available were analysed to estimate recent population trends. Populations of all three species of vulture remained at a low level. The previously rapid decline of White-rumped Vulture has slowed and may have reversed since the ban on veterinary use of diclofenac in India in 2006. A few thousand of this species, possibly up to the low tens of thousands, remained in India in 2015. The population of Indian Vulture continued to decline, though probably at a much slower rate than in the 1990s. This remains the most numerous of the three species in India with about 12,000 individuals in 2015 and a confidence interval ranging from a few thousands to a few tens of thousands. The trend in the rarest species, Slender-billed Vulture, which probably numbers not much more than 1,000 individuals in India, cannot be determined reliably.

Veterinary use of the non-steroidal anti-inflammatory drug diclofenac on domesticated ungulates caused populations of resident Gyps vultures in the Indian sub-continent to collapse. The birds died when they fed on carrion from treated animals. Veterinary diclofenac was banned in 2006 and meloxicam was advocated as a ‘vulture-safe’ alternative. We examine the effectiveness of the 2006 ban, whether meloxicam has replaced diclofenac, and the impact of these changes on vultures. Drug residue data from liver samples collected from ungulate carcasses in India since 2004 demonstrate that the prevalence of diclofenac in carcasses in 2009 was half of that before the ban and meloxicam prevalence increased by 44%. The expected vulture death rate from diclofenac per meal in 2009 was one-third of that before the ban. Surveys at veterinary clinics show that diclofenac use in India began in 1994, coinciding with the onset of rapid Gyps declines ascertained from measured rates of declines. Our study shows that one pharmaceutical product has had a devastating impact on Asia's vultures. Large-scale research and survey were needed to detect, diagnose and quantify the problem and measure the response to remedial actions. Given these difficulties, other effects of pharmaceuticals in the environment may remain undetected.

Contamination of their carrion food supply with the non-steroidal anti-inflammatory drug diclofenac has caused rapid population declines across the Indian subcontinent of three species of Gyps vultures endemic to South Asia. The governments of India, Pakistan and Nepal took action in 2006 to prevent the veterinary use of diclofenac on domesticated livestock, the route by which contamination occurs. We analyse data from three surveys of the prevalence and concentration of diclofenac residues in carcasses of domesticated ungulates in India, carried out before and after the implementation of a ban on veterinary use. There was little change in the prevalence and concentration of diclofenac between a survey before the ban and one conducted soon after its implementation, with the percentage of carcasses containing diclofenac in these surveys estimated at 10.8 and 10.7%, respectively. However, both the prevalence and concentration of diclofenac had fallen markedly 7–31 months after the implementation of the ban, with the true prevalence in this third survey estimated at 6.5%. Modelling of the impact of this reduction in diclofenac on the expected rate of decline of the oriental white-backed vulture (Gyps bengalensis) in India indicates that the decline rate has decreased to 40% of the rate before the ban, but is still likely to be rapid (about 18% year−1). Hence, further efforts to remove diclofenac from vulture food are still needed if the future recovery or successful reintroduction of vultures is to be feasible.

Use of the veterinary drug diclofenac is responsible for bringing three species of Gyps vultures endemic to South Asia to the brink of extinction, and the Government of India banned veterinary use of the drug in May 2006. To evaluate the effectiveness of the ban we undertook surveys of > 250 veterinary and general pharmacies in 11 Indian states from November 2007 to June 2010. Twelve different classes of non-steroidal anti-inflammatory drugs (NSAIDs) were purchased from 176 pharmacies. Other than meloxicam (of negligible toxicity to vultures at likely concentrations in their food), diclofenac and ketoprofen (both toxic to vultures), little is known of the safety or toxicity of the remaining nine NSAIDs on sale. Meloxicam was the most commonly encountered drug, sold in 70% of pharmacies, but 50% of the meloxicam brands sold had paracetamol (acetaminophen) as a second ingredient. Diclofenac and ketoprofen were recorded in 36 and 29% of pharmacies, respectively, with states in western and central India having the highest prevalence of diclofenac (44–45%). Although the large number of manufacturers and availability of meloxicam is encouraging, the wide range of untested NSAIDs and continued availability of diclofenac is a major source of concern. Circumvention of the 2006 diclofenac ban is being achieved by illegally selling forms of diclofenac manufactured for human use for veterinary purposes. To provide a safer environment for vultures in South Asia we recommend reducing the size of vials of diclofenac meant for human use, to increase the costs of illegal veterinary use, and taking action against pharmaceutical manufacturers and pharmacies flouting the diclofenac ban.